September 26, 2019
Amgen China launches “A Healthy Heart for China” campaign with its partner to call attention to cardiovascular health
Shanghai, China (September 26, 2019) —— In recognition of World Heart Day, Amgen China launched “A Healthy Heart for China” campaign with its industry partner. The campaign calls for action on cholesterol management through a heart-healthy lifestyle and medication to manage lipid level and minimize the risk of life-changing cardiovascular (CV) events.
Synchronously, Amgen released key findings of a global survey involving heart attack survivors across 13 countries, which evaluated survivors’ perceptions and awareness of the connection between cholesterol and CV events. The survey findings revealed that 78% of respondents in China do not consider high cholesterol as the most associated risk factor for the recurrence of a heart attack.1
Chinese respondents fall short on understanding of "bad" types of cholesterol
Globally, more than 40% of patients who have had a heart attack will have another CV event within two years. 2Lipids, such as low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, are one of the most important risk factors for heart attack.3
The survey findings show that while heart attack survivors are proactively trying to improve their cardiovascular health, they may not fully understand the importance of lowering high LDL-C to reduce their risk of another heart attack: 32% of Chinese respondents do not think or do not know that there are two types of cholesterol, which is significantly higher than the global average percentage. 1,4
The key to manage cholesterol effectively is to raise awareness
In recent years, prevalence of dyslipidemia in the Chinese population has gradually increased, which is characterized by the increase of LDL-C. However, the total treatment rate of high LDL-C is only at 3.6%, while very high-risk patients’ LDL-C treatment rate is only at 14.5%. 5A lack of understanding of LDL-C could lead to real risks for patients’ cholesterol management and heart health.
The survey findings show that 67% of Chinese heart attack survivors view CVD as the most serious threat to their health, and more than 50% feel anxious or fearful about the recurrence of a heart attack. However, in terms of their views toward means of reducing heart attack risk, 44% of Chinese survivors do not realize that they can lower the risk of heart attack through lifestyle changes and prescription medication. It is urgent for health communities to strengthen their patients’ education on managing risk of CVD events recurrence. 1
Protecting a Healthy Heart for China is a long-term process
Professional cardiology societies around the world now recognize that lower cholesterol minimizes the risk of atherosclerotic CV diseases (ASCVD) events. 6Therefore, long-term and effective cholesterol management plays a significant role in CVD events prevention.
2019 European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Guidelines call for more intensive reduction of LDL-C across CV risk categories and emphasize that “lower is better”: the lower the LDL-C values, the lower the risk of future CV events; and for very high-risk patients, an LDL-C reduction of >50% from baseline AND an LDL-C goal of <55 mg/dL are recommended. 7
As a biotechnology pioneer, Amgen is committed to serving patients and accelerating the transformation of the healthcare model from "Break and Fix" to "Predict and Prevent" by unlocking the potential of biology. In China, we support the building of a “Predict and Prevent” healthcare ecosystem based on local demands, so as to improve the quality of life of Chinese patients and guard the "Healthy Heart for China" for the realization of the "Healthy China 2030" vision.
About the Survey
The research was commissioned by Amgen and conducted by KRC Research, an independent global public opinion research consultancy. A total of 3,236 online surveys were completed by post-myocardial infarction (MI) patients aged 40 or older in 13 different countries, including 250 participants from China. Participating countries included the United States, Mexico, Brazil, Canada, United Kingdom, France, Germany, Spain, Italy, the Netherlands, China, South Korea, and Japan. Data collection took place from June 21 to July 18, 2019.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients in more than 100 countries and regions worldwide and is developing a pipeline of medicines with breakaway potential.
For more information, visit http://www.amgen.com and follow us on http://www.twitter.com/amgen.
About Amgen China
Amgen entered China in 2012 on a mission to serve patients by using science and biotechnology to improve health for Chinese patients and societies. With its headquarters in Shanghai, Amgen China is present in more than 50 cities across the country. In China, Amgen strives to bring innovative therapies to patients in a bid to address the huge unmet needs in cardiovascular disease, oncology and bone health.
Amgen inaugurated the Asia Research and Development Center in Shanghai in 2014 as part of efforts to pursue the best in scientific innovation. With a biology-first approach, the center is committed to translating the promise of science and biotechnology into therapies that have the power to save lives and restore health.
For more information, visit http://www.amgen.com
- Global Cholesterol Disease State Education Survey (Country Report: China), Amgen; 2019
- Punekar RS, et al. Clin Cardiol. 2015; 38, 8, 483–491.
- Yusuf S, et al. Lancet. 2004;364:937-952.
- Global Cholesterol Disease State Education Survey, Amgen; 2019
- Mei Zhang, et al. Int J-cardiol. 2018 Jun 1;260:196-203
- National Center for Cardiovascular Diseases, China. Report on Cardiovascular Diseases in China, 2016. Beijing: ECPH.
- Mach F, Baigent C, Catapano A L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk[J]. Atherosclerosis, 2019.